Physician profile
Marc Schwartz
NPI 1245454990
$7,101.51
in general payments reported to CMS, 2019-2025
20 companies · $23.29 in 2025
The $23.29 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $29.99 · 2021: $196 · 2022: $279 · 2023: $164 · 2024: $6,067 · 2025: $23.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Food and Beverage: $207 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Food and Beverage | $206.92 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,097.49 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.55 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $195.55 | 2019-2024 | Rexulti |
| Tris Pharma INC | $183.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $62.24 | 2019-2025 | Spravato |
| Allergan, INC. | $61.49 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $58.40 | 2019 | |
| Corium, LLC | $28.34 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $23.49 | 2023 | Quviviq |
| Almatica Pharma LLC | $20.97 | 2021 | |
| Vertical Pharmaceuticals, LLC | $20.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.90 | 2019 | |
| Acadia Pharmaceuticals INC | $19.72 | 2021 | |
| Neos Therapeutics, LP | $19.01 | 2019 | |
| Neurocrine Biosciences, INC. | $17.19 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $14.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.64 | 2021 | |
| Alkermes, INC. | $12.91 | 2021 | |
| Lundbeck LLC | $12.91 | 2019 | |
| Adlon Therapeutics L.P. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.